In 2023, Lu Yong—the real-life inspiration behind the acclaimed Chinese film Dying to Survive—returned to India, drawing widespread public attention. Years earlier, Lu had been prosecuted for helping leukemia patients purchase affordable Indian generic imatinib (Gleevec), but was ultimately acquitted due to strong public support and legal considerations. He became a symbol of grassroots efforts to improve drug accessibility and healthcare reform in China. This time, however, his trip was not for drug procurement but as part of a nonprofit initiative promoting civil-level medical exchanges between China and India. He focused on issues such as generic drug quality, patient safety, and cross-border healthcare collaboration. Lu noted that thanks to China’s expanding national health insurance coverage, many anti-cancer drugs are now reimbursable, significantly reducing patients’ financial burdens—though challenges remain for rare diseases and newer therapies. He hopes his visit will help facilitate more legal, safe, and affordable treatment options. Lu Yong’s journey reflects both individual compassion amid systemic gaps and China’s ongoing healthcare reforms responding to public needs. His story reminds us that institutions must embody humanity, and society should embrace empathy—especially when lives are at stake.
2023年，电影《我不是药神》的现实原型人物陆勇再次前往印度，引发公众广泛关注。陆勇曾因帮助白血病患者代购印度仿制药‘格列卫’而被起诉，后因社会舆论支持和法律考量被免于起诉，成为推动中国药品可及性与医疗改革的重要象征。此次重返印度，他并非为代购药物，而是以公益身份参与中印民间医药交流活动，关注仿制药质量、患者用药安全及跨境医疗合作等议题。陆勇表示，随着中国医保政策不断完善，许多抗癌药已纳入报销目录，患者负担大幅减轻，但部分罕见病和新药仍存在可及性难题。他希望通过此次访问，促进更多合法、安全、可负担的治疗方案落地。陆勇的经历不仅体现了个体在制度缝隙中的善意与勇气，也折射出中国医疗体系在改革中不断回应民生需求的努力。他的行动提醒我们：在生命面前，制度应更具温度，社会应更有包容。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/12204.html